Joint Initiative, “Safe Anaesthesia – ASAP,” Is
to Improve Anesthesia Care in Low Resource Countries
Masimo (NASDAQ: MASI) announced Sunday at the World
Congress of Anaesthesiologists (WCA) in Hong Kong that it has
become the first Global Impact Partner of the World Federation of
Societies of Anaesthesiologists (WFSA). The four-year partnership,
“Safe Anaesthesia – ASAP” (Anesthesia Safety Action Plan), will
initially identify one country with poor access to safe anesthesia,
and will work toward implementing programs and training designed to
improve anesthesia care and safe surgery outcomes.
In 2015, the Lancet Commission on Global Surgery reported that
approximately 5 billion people – the majority of the world’s
population – do not have access to safe, affordable anesthesia and
surgical care, and estimated that 16.9 million die annually as a
result.1 These deaths are attributable to a lack of infrastructure,
essential monitoring equipment, and drugs, as well as a shortage of
adequately trained healthcare workers.1
As part of the first phase of the joint project between the WFSA
and Masimo, a high burden country will be identified as the ASAP’s
focus. Key to the project’s success will be bringing together all
stakeholders, including the government, so that infrastructure gaps
can be identified, needs assessed, and the ASAP implemented.
Implementation will involve a combination of training courses and
other educational materials, distribution of essential drugs, and
installation of and training on medical equipment. Training,
monitoring, and project assessment will be ongoing throughout the
four years, with an emphasis on ensuring that the improvements are
sustainable.
Lifebox, an NGO (not-for-profit, non-governmental organization)
dedicated to improving safe surgery, will also be assisting with
training support. Kristine Stave, Chief Operating Officer of
Lifebox, commented, “Lifebox works with colleagues on the front
line of the global surgical safety crisis to support long-term
improvement in the safety and quality of anesthesia care. We know
firsthand the challenges of environment, equipment, education – and
we also know the extraordinary capacity for positive change that
the best partnerships can bring. We’re proud to be a part of this
urgent and historic undertaking between the WFSA and Masimo, and to
be delivering our shared goal of making anesthesia safer for
millions of patients worldwide.”
WFSA has been uniting anesthesiologists globally for more than
60 years. With a network of hundreds of thousands of
anesthesiologists in more than 150 countries, WFSA is well
positioned to deliver programs that facilitate learning, and
promote the highest standard of anesthesia care globally. Masimo,
whose clinically leading SET® pulse oximetry is used to monitor
over 100 million patients across the world, has made a commitment
to become a WFSA Global Impact Partner in 2016. Together, WFSA and
Masimo created the ASAP action plan, which it is hoped will become
a model for high burden countries to improve anesthesia care and
safe surgery outcomes.
Dr. David Wilkinson, President of the WFSA, stated, “The WFSA is
delighted to announce Masimo as our first Global Impact Partner. We
work together to improve patient care and access to safe anesthesia
around the world.”
Dr Adrian Gelb, Chair of the WFSA’s Safety and Quality Committee
and Professor of Anaesthesia and Perioperative Care at the UCSF
School of Medicine, added, “It is essential that we make safe and
affordable anesthesia and surgical care available to every patient
in every country. Investment in national anesthesia plans, together
with key stakeholders, will ensure that specific country needs are
met most appropriately in order to make the biggest impact.”
“At Masimo, we believe that regardless of where you live or
where you were born, access to quality healthcare that is dignified
and safe – including safe, effective anesthesia and surgery – is a
human right, not a privilege,” said Joe Kiani, Founder and CEO of
Masimo. “We are delighted to be the first partner with the WFSA in
bringing much-needed help, with Safe Anaesthesia – ASAP, to areas
of the world blighted by needless deaths.”
Mr. Kiani added: “The new millennium goal is no longer to
provide all of our people access to health care, but to provide all
of our people access to health care that is systematically safe and
dignified.”
@MasimoInnovates | #Masimo | @0X2020 |
@wfsaorg | #WCA2016
Reference
- Meara JG, Leather AJ, Hagander L et al.
Global Surgery 2030: Evidence and solutions for achieving health,
welfare, and economic development. Surgery. 2015
Jul;158(1):3-6.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative
noninvasive monitoring technologies. Our mission is to improve
patient outcomes and reduce the cost of care by taking noninvasive
monitoring to new sites and applications. In 1995, the company
debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse
oximetry, which has been shown in multiple studies to significantly
reduce false alarms and accurately monitor for true alarms. Masimo
SET® is estimated to be used on more than 100 million patients in
leading hospitals and other healthcare settings around the world.
In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology,
allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more
recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index
(ORI™), in addition to SpO2, pulse rate, and perfusion index (PI).
In 2014, Masimo introduced Root®, an intuitive patient monitoring
and connectivity platform with the Masimo Open Connect™ (MOC-9™)
interface. Masimo is also taking an active leadership role in
mHealth with products such as the Radius-7™ wearable patient
monitor and the MightySat™ fingertip pulse oximeter. Additional
information about Masimo and its products may be found at
www.masimo.com. All published clinical studies on Masimo products
can be found at
http://www.masimo.com/cpub/clinical-evidence.htm.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential success of the ASAP. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of
which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as
a result of various risk factors, including, but not limited to:
risks related to our assumptions regarding the repeatability of
clinical results; risks related to our belief that Masimo's unique
noninvasive measurement technologies contribute to positive
clinical outcomes and patient safety; risks related to our belief
that Masimo noninvasive medical breakthroughs provide
cost-effective solutions with comparable accuracy and unique
advantages, including: immediate and continuous results that enable
earlier treatment without causing invasive trauma in all patients
and in every clinical situation; as well as other factors discussed
in the "Risk Factors" section of our most recent reports filed with
the Securities and Exchange Commission ("SEC"), which may be
obtained for free at the SEC's website at www.sec.gov. Although we
believe that the expectations reflected in our forward-looking
statements are reasonable, we do not know whether our expectations
will prove correct. All forward-looking statements included in this
press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of today's date. We do not undertake any obligation to
update, amend or clarify these statements or the "Risk Factors"
contained in our most recent reports filed with the SEC, whether as
a result of new information, future events or otherwise, except as
may be required under the applicable securities laws.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160829006049/en/
MasimoIrene Paigah, 858-859-7001irenep@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2024 to May 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From May 2023 to May 2024